Harnessing the Benefits of Biobanks
Author:
- 1 January 2005
- journal article
- review article
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 33 (1) , 22-30
Abstract
We have a thriving biotechnology industry in the United States. There are over 1,450 biotechnology companies developing diagnostic and treatment technologies in medicine, creating more nutritional foods, and innovating new industrial processes. Yet this $28.5 billion sector of the economy is not without controversy. The “bio” in biotechnology comes from living, biological entities - people, plants, animals, and even bacteria. In the realm of biobanking, people are the source of the raw material for the discovery of genes for research, diagnosis, and therapy, raising a host of issues about rights and responsibilities, fiduciary duties and societal obligations.Keywords
This publication has 10 references indexed in Scilit:
- Genes and patent policy: rethinking intellectual property rightsNature Reviews Genetics, 2002
- Diagnostic testing fails the testNature, 2002
- Embryonic Stem Cell Lines Derived from Human BlastocystsScience, 1998
- Privacy bill under fire from researchersNature, 1998
- Whose DNA Is It, Anyway?Science, 1997
- Ethical issues in genetic research: disclosure and informed consentNature Genetics, 1997
- AnnouncementsJournal of Medical Microbiology, 1997
- Lessons about NIDDM from the Pima IndiansThe Lancet, 1996
- Ownership of the human genomeNature, 1996
- Student, Heal Thyself: Self-Management Interventions in the ClassroomContemporary Psychology, 1995